BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33989224)

  • 1. Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection.
    Watanabe K; Shimodaira Y; Takahashi S; Fukuda S; Koizumi S; Matsuhashi T; Iijima K
    Am J Gastroenterol; 2021 Aug; 116(8):1632-1637. PubMed ID: 33989224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors.
    Saruta Y; Watanabe K; Tsuji T; Takahashi Y; Matsuzawa H; Yoshida T; Takahashi S; Shimodaira Y; Matsuhashi T; Iijima K
    J Gastroenterol Hepatol; 2023 Jun; 38(6):940-947. PubMed ID: 36882162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: A nationwide database study.
    Tsujita K; Deguchi H; Uda A; Sugano K
    J Cardiol; 2020 Jul; 76(1):51-57. PubMed ID: 32184027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study.
    Kambara H; Hosohata K; Nakatsuji T; Ueno S; Oyama S; Inada A; Niinomi I; Wakabayashi T; Iwanaga K
    Pharmazie; 2020 Oct; 75(10):527-530. PubMed ID: 33305731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients.
    Barletta JF; Sclar DA
    Crit Care; 2014 Dec; 18(6):714. PubMed ID: 25540023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.
    Freedberg DE; Salmasian H; Friedman C; Abrams JA
    Am J Gastroenterol; 2013 Nov; 108(11):1794-801. PubMed ID: 24060760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study.
    Kojima Y; Takeuchi T; Sanomura M; Higashino K; Kojima K; Fukumoto K; Takata K; Sakamoto H; Sakaguchi M; Tominaga K; Higuchi K
    Digestion; 2018; 97(1):70-75. PubMed ID: 29393198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
    Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
    Linsky A; Gupta K; Lawler EV; Fonda JR; Hermos JA
    Arch Intern Med; 2010 May; 170(9):772-8. PubMed ID: 20458084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
    Kiyotoki S; Nishikawa J; Sakaida I
    Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
    Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection.
    Barletta JF; El-Ibiary SY; Davis LE; Nguyen B; Raney CR
    Mayo Clin Proc; 2013 Oct; 88(10):1085-90. PubMed ID: 24012413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of proton pump inhibitor use on risk of Clostridium difficile infection: a hospital cohort study.
    Park YH; Seong JM; Cho S; Han HW; Kim JY; An SH; Gwak HS
    J Gastroenterol; 2019 Dec; 54(12):1052-1060. PubMed ID: 31187275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor.
    Gordon D; Young LR; Reddy S; Bergman C; Young JD
    J Hosp Infect; 2016 Feb; 92(2):173-7. PubMed ID: 26616410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis.
    Oshima T; Wu L; Li M; Fukui H; Watari J; Miwa H
    J Gastroenterol; 2018 Jan; 53(1):84-94. PubMed ID: 28744822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection.
    Cao F; Chen CX; Wang M; Liao HR; Wang MX; Hua SZ; Huang B; Xiong Y; Zhang JY; Xu YL
    J Hosp Infect; 2018 Jan; 98(1):4-13. PubMed ID: 28842261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients.
    Ro Y; Eun CS; Kim HS; Kim JY; Byun YJ; Yoo KS; Han DS
    Gut Liver; 2016 Jul; 10(4):581-6. PubMed ID: 27021503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.
    Faleck DM; Salmasian H; Furuya EY; Larson EL; Abrams JA; Freedberg DE
    Am J Gastroenterol; 2016 Nov; 111(11):1641-1648. PubMed ID: 27575714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.